Transdermal anti-inflammatory therapy for aqueous deficiency
1Faculty of Medicine and Health, School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.
Summary
Topical anti-inflammatory drugs poorly reach the lacrimal gland, limiting their effectiveness in treating dry eye disease. Alternative delivery methods are needed to improve drug access and aqueous flow for dry eye patients.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Lacrimal gland inflammation significantly impairs aqueous production, contributing to dry eye disease.
- Ocular surface inflammation in dry eye can result from reduced aqueous delivery from an inflamed lacrimal gland.
- Inflamed lacrimal glands release high concentrations of inflammatory mediators.
Purpose of the Study:
- To review evidence on the limited access of topical anti-inflammatory drugs to the lacrimal gland.
- To examine challenges in treating dry eye disease with topical anti-inflammatory drugs, using cyclosporine as an example.
- To compare topical drug delivery limitations with the potential of transdermal applications for treating aqueous deficiency.
Main Methods:
- Review of existing scientific literature on drug delivery to the lacrimal gland.
- Analysis of therapeutic challenges associated with topical anti-inflammatory drug administration in dry eye.
- Comparison of topical ocular drug delivery with transdermal delivery strategies.
Main Results:
- Topical anti-inflammatory drugs demonstrate limited access to the lacrimal gland.
- Poor drug access to the lacrimal gland is a significant barrier to treating aqueous deficiency.
- Drug efficacy is hindered by short on-eye residence times and suboptimal drop characteristics (temperature, pH, tonicity).
Conclusions:
- Current topical anti-inflammatory treatments have limited capacity to increase aqueous flow by reducing lacrimal gland inflammation.
- Transdermal drug delivery presents a potential alternative for achieving prolonged therapeutic effects at the lacrimal gland.
- Addressing poor lacrimal gland drug penetration is crucial for advancing dry eye disease treatment.
Related Concept Videos
01:22Drug Delivery: Miscellaneous Routes
541
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
541
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
01:27Open Angle Glaucoma: Treatment
753
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
753
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
01:29Inflammatory Bowel Disease IV: Pharmacological Management
240
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
240
01:27Bioavailability Enhancement: Drug Permeability Enhancement
20
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
20